Advances in ALL at ASH Meeting Include New Blinatumomab Data and More

(MedPage Today) -- In the phase III ECOG-ACRIN E1910 study presented at the American Society of Hematology (ASH) annual meeting, consolidation chemotherapy with blinatumomab (Blincyto) improved overall survival in patients with newly diagnosed...